254 related articles for article (PubMed ID: 29136645)
1. A 4-miRNA signature to predict survival in glioblastomas.
Hermansen SK; Sørensen MD; Hansen A; Knudsen S; Alvarado AG; Lathia JD; Kristensen BW
PLoS One; 2017; 12(11):e0188090. PubMed ID: 29136645
[TBL] [Abstract][Full Text] [Related]
2. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
[TBL] [Abstract][Full Text] [Related]
3. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma.
Khalil S; Fabbri E; Santangelo A; Bezzerri V; Cantù C; Di Gennaro G; Finotti A; Ghimenton C; Eccher A; Dechecchi M; Scarpa A; Hirshman B; Chen C; Ferracin M; Negrini M; Gambari R; Cabrini G
Oncotarget; 2016 May; 7(19):28195-206. PubMed ID: 27057640
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA expression patterns in the malignant progression of gliomas and a 5-microRNA signature for prognosis.
Yan W; Li R; Liu Y; Yang P; Wang Z; Zhang C; Bao Z; Zhang W; You Y; Jiang T
Oncotarget; 2014 Dec; 5(24):12908-15. PubMed ID: 25415048
[TBL] [Abstract][Full Text] [Related]
5. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
[TBL] [Abstract][Full Text] [Related]
6. In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.
Kreth S; Limbeck E; Hinske LC; Schütz SV; Thon N; Hoefig K; Egensperger R; Kreth FW
Acta Neuropathol; 2013 May; 125(5):671-81. PubMed ID: 23340988
[TBL] [Abstract][Full Text] [Related]
7. Post-transcriptional regulation of O(6)-methylguanine-DNA methyltransferase MGMT in glioblastomas.
Ramakrishnan V; Kushwaha D; Koay DC; Reddy H; Mao Y; Zhou L; Ng K; Zinn P; Carter B; Chen CC
Cancer Biomark; 2011-2012; 10(3-4):185-93. PubMed ID: 22674304
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-target cross-talks: Key players in glioblastoma multiforme.
Toraih EA; Aly NM; Abdallah HY; Al-Qahtani SA; Shaalan AA; Hussein MH; Fawzy MS
Tumour Biol; 2017 Nov; 39(11):1010428317726842. PubMed ID: 29110584
[TBL] [Abstract][Full Text] [Related]
9. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
10. Risk Score based on microRNA expression signature is independent prognostic classifier of glioblastoma patients.
Sana J; Radova L; Lakomy R; Kren L; Fadrus P; Smrcka M; Besse A; Nekvindova J; Hermanova M; Jancalek R; Svoboda M; Hajduch M; Slampa P; Vyzula R; Slaby O
Carcinogenesis; 2014 Dec; 35(12):2756-62. PubMed ID: 25322872
[TBL] [Abstract][Full Text] [Related]
11. Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.
Yerukala Sathipati S; Huang HL; Ho SY
BMC Genomics; 2016 Dec; 17(Suppl 13):1022. PubMed ID: 28155650
[TBL] [Abstract][Full Text] [Related]
12. Expression level of miRNAs on chromosome 14q32.31 region correlates with tumor aggressiveness and survival of glioblastoma patients.
Shahar T; Granit A; Zrihan D; Canello T; Charbit H; Einstein O; Rozovski U; Elgavish S; Ram Z; Siegal T; Lavon I
J Neurooncol; 2016 Dec; 130(3):413-422. PubMed ID: 27573219
[TBL] [Abstract][Full Text] [Related]
13. A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
Inamoto T; Uehara H; Akao Y; Ibuki N; Komura K; Takahara K; Takai T; Uchimoto T; Saito K; Tanda N; Yoshikawa Y; Minami K; Hirano H; Nomi H; Kato R; Hayashi T; Azuma H
Dis Markers; 2018; 2018():5468672. PubMed ID: 30026881
[TBL] [Abstract][Full Text] [Related]
14. Interactions of miR-323/miR-326/miR-329 and miR-130a/miR-155/miR-210 as prognostic indicators for clinical outcome of glioblastoma patients.
Qiu S; Lin S; Hu D; Feng Y; Tan Y; Peng Y
J Transl Med; 2013 Jan; 11():10. PubMed ID: 23302469
[TBL] [Abstract][Full Text] [Related]
15. Identification of IGF-1-enhanced cytokine expressions targeted by miR-181d in glioblastomas via an integrative miRNA/mRNA regulatory network analysis.
Ho KH; Chen PH; Hsi E; Shih CM; Chang WC; Cheng CH; Lin CW; Chen KC
Sci Rep; 2017 Apr; 7(1):732. PubMed ID: 28389653
[TBL] [Abstract][Full Text] [Related]
16. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.
Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D
Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935
[TBL] [Abstract][Full Text] [Related]
17. Integrative miRNA analysis identifies hsa-miR-3154, hsa-miR-7-3, and hsa-miR-600 as potential prognostic biomarker for cervical cancer.
Zeng Y; Wang KX; Xu H; Hong Y
J Cell Biochem; 2018 Feb; 119(2):1558-1566. PubMed ID: 28771797
[TBL] [Abstract][Full Text] [Related]
18. miR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of O6-methylguanine-DNA methyltransferase.
Chen H; Li X; Li W; Zheng H
J Transl Med; 2015 Feb; 13():69. PubMed ID: 25890369
[TBL] [Abstract][Full Text] [Related]
19. PI3 kinase pathway regulated miRNome in glioblastoma: identification of miR-326 as a tumour suppressor miRNA.
Nawaz Z; Patil V; Paul Y; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Mol Cancer; 2016 Nov; 15(1):74. PubMed ID: 27871300
[TBL] [Abstract][Full Text] [Related]
20. Serum microRNA profiling in patients with glioblastoma: a survival analysis.
Zhao H; Shen J; Hodges TR; Song R; Fuller GN; Heimberger AB
Mol Cancer; 2017 Mar; 16(1):59. PubMed ID: 28284220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
